BridgeBio Collaborated with Resilience to Manufacture and Advance BBP-812 for Canavan Disease and BP-631 for Congenital Adrenal Hyperplasia
Shots:
- Resilience will receive future development & approval milestones along with royalties on BBP-631 & BBP-812. BridgeBio will transfer its manufacturing process for its lead AAV-based gene therapy candidates to Resilience’s network of gene therapy sites
- Resilience will lead ongoing clinical development manufacturing needs & will serve as the primary commercial manufacturer for both programs if successful along with the primary manufacturer for future clinical projects across BridgeBio’s gene therapy portfolio
- BBP-812, an AAV9 gene therapy for Canavan disease & received FTD, Rare Pediatric Drug Designation & ODD from the US FDA & EMA. BBP-631, an AAV5 gene therapy developed to treat CAH due to 21-hydroxylase deficiency at its source
Ref: Businesswire | Image: BridgeBio
Related News:- BridgeBio Pharma Presents P-I/II (CANaspire) Trial Results of BBP-812 for the Treatment of Canavan Disease at CNS 2022
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
